Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.
about
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor ImmunityDisruptive environmental chemicals and cellular mechanisms that confer resistance to cell deathPathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancerp38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemiaOver-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistanceToll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis.Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion.MicroRNA-22 impairs anti-tumor ability of dendritic cells by targeting p38.Tumor cell p38 MAPK: A trigger of cancer bone osteolysisCombined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cellsConstitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.Immunotherapy of cancer in 2012.p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3AAn array of possibilities in cancer research using cytokine antibody arrays.Immunodeficiency and immunotherapy in multiple myeloma.Cellular mechanisms of multiple myeloma bone diseaseMaytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.Human breast cancer-derived soluble factors facilitate CCL19-induced chemotaxis of human dendritic cells.Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.Tumor associated regulatory dendritic cells.Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Tumor-altered dendritic cell function: implications for anti-tumor immunity.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.Future agents and treatment directions in multiple myeloma.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Effects of Gekko sulfated polysaccharide-protein complex on the defective biorheological characters of dendritic cells under tumor microenvironment.Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK.Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation.BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growthDendritic cells in cancer immunotherapy: vaccines or autologous transplants?Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition.IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2.MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients.
P2860
Q28075996-B7500E32-1980-4F4A-A126-DFEB1D52F6FEQ28080874-CFA20068-EEB2-42B5-AFFA-2AF1C939BD47Q28392626-CA23E416-20A8-4A0F-9804-2EFC660652C7Q30422500-20562579-8754-4FF0-9AD4-FB2547D10BC6Q33942806-E8871DF2-7298-4AC2-9236-726C17FC1FF1Q34011555-F9A91BEA-1A7E-4270-87B9-55ED71874FADQ34175179-75492680-0507-4B8C-8FB9-6E8D7D562094Q34316853-CE94A2B3-D6D3-4D29-AC87-F92001406FA6Q34415459-0AD76461-3A34-43A4-90A5-813FEA5542A9Q35234933-35061241-1F37-4E16-BAE6-1D7520609D8DQ35662843-E99F7765-CF08-4A21-9A02-9AE3C492E75BQ35802152-14571AFF-106F-4D2F-9522-A960AFBD5836Q35848756-A0D218BF-8BDC-4792-A839-56780DB686A6Q36054631-ADDF8A26-D337-40B0-BF87-E47CF6328E6AQ36243536-C003EE8F-F1B4-4BE2-B1FF-CDFB4DC6B57BQ36476432-96F14373-86E4-4C95-ACBE-BB1075F93AD2Q36528775-C196E1F4-FD47-4A94-B801-BA75B8C30613Q36787259-BDCAAF4C-53AB-4B3A-B09A-2B96E0D7150CQ36904977-554FC084-6AA2-4874-8852-DA26D3E61F67Q36925346-63E9FE38-C449-40D4-BAA1-8C4C00685022Q37019223-73C6CA01-F49C-4C15-9A78-5EB9E6733468Q37121744-FDD4C2CD-2FE9-4629-BDD9-ACE6EA00BAC8Q37144907-1C38E382-48F8-4020-B075-98110B9A9D23Q37513871-ED523B7E-F16B-4AAE-950A-00BE4383FB09Q37735454-EF233AE0-D0B9-433E-A5AC-85CB8B6C1F60Q37993359-F02EAB81-8CD1-499F-8F51-52DC768EA2EDQ38008379-FC53F691-B273-45CC-AE88-E02876E1AE67Q38123166-1910AF31-1DE8-4112-BD8B-B6345DADB5B9Q38155039-28C90E41-D23F-41FD-BFA0-B771085B668AQ38172300-52328F4B-96B1-4B3C-84D5-A48AA0E3B844Q38932298-18BEF4C8-D81C-4934-9E4C-3B9FC5065562Q39438805-17CAD174-13FC-482F-8713-FCBE51AE3222Q39474847-3EA8918C-54F6-4C25-BC90-05C6A66BD9C5Q39606399-B811AECD-E8E8-46FC-8D06-84A54B03FA47Q39982625-06647888-F4CA-4B39-B861-B0CE9BCBF447Q40195083-5D7B766D-360A-440E-B73C-6F90F3AA1DA3Q41520681-1D023E35-A46E-4BF6-B79A-EF2F5F91953CQ42321642-243DC9D7-6AB0-46D1-B0BC-A2570382DBCCQ42914474-8090DE93-007D-4B44-889E-E5B0435E6E7CQ43497561-D2C2D54F-F7BD-4F8D-873F-D15A1DB1CC67
P2860
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tumor evasion of the immune sy ...... tic cells in multiple myeloma.
@en
Tumor evasion of the immune sy ...... tic cells in multiple myeloma.
@nl
type
label
Tumor evasion of the immune sy ...... tic cells in multiple myeloma.
@en
Tumor evasion of the immune sy ...... tic cells in multiple myeloma.
@nl
prefLabel
Tumor evasion of the immune sy ...... tic cells in multiple myeloma.
@en
Tumor evasion of the immune sy ...... tic cells in multiple myeloma.
@nl
P2093
P2860
P1433
P1476
Tumor evasion of the immune sy ...... tic cells in multiple myeloma.
@en
P2093
Jianfei Qian
Larry W Kwak
Michele Wezeman
Siqing Wang
P2860
P304
P356
10.1182/BLOOD-2005-06-2486
P407
P577
2005-11-15T00:00:00Z